Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Other Non-Current Assets (2016 - 2025)

Ironwood Pharmaceuticals' Other Non-Current Assets history spans 17 years, with the latest figure at $4.5 million for Q4 2025.

  • For Q4 2025, Other Non-Current Assets fell 23.99% year-over-year to $4.5 million; the TTM value through Dec 2025 reached $4.5 million, down 23.99%, while the annual FY2025 figure was $4.5 million, 23.99% down from the prior year.
  • Other Non-Current Assets for Q4 2025 was $4.5 million at Ironwood Pharmaceuticals, down from $4.8 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $6.3 million in Q3 2024 and bottomed at $485000.0 in Q3 2021.
  • The 5-year median for Other Non-Current Assets is $2.2 million (2021), against an average of $2.7 million.
  • The largest annual shift saw Other Non-Current Assets crashed 47.51% in 2022 before it soared 1132.35% in 2024.
  • A 5-year view of Other Non-Current Assets shows it stood at $500000.0 in 2021, then changed by 0.0% to $500000.0 in 2022, then surged by 621.6% to $3.6 million in 2023, then soared by 64.16% to $5.9 million in 2024, then decreased by 23.99% to $4.5 million in 2025.
  • Per Business Quant, the three most recent readings for IRWD's Other Non-Current Assets are $4.5 million (Q4 2025), $4.8 million (Q3 2025), and $5.2 million (Q2 2025).